MMGH Consulting Logo

Contributing to a world free from vaccine-preventable diseases

We help increase access to, and use of, vaccines by supporting public and non-profit clients with developing better policies, products and tools that strengthen immunization and disease control programmes.

Our Services

A world where everyone enjoys a life free from vaccine-preventable diseases

Explore Our Work

Vaccines are responsible for preventing an estimated 2-3 million deaths per year, yet sadly, 1.5 million people worldwide are still dying from vaccine-preventable diseases.

Using our public health experience and implementation and academic backgrounds, we have assembled an optimal team to ensure that all immunization programmes have the best chance of success.

Service Offerings

Access

Enable improved access to vaccines and diagnostic products.

Programme Implementation

Support the effective implementation of immunization and diagnostic programmes.

Policy and Strategy

Strengthen disease control policies and strategies by advising on their development

Evaluation

Conduct evaluations to support the productive and beneficial functioning of organisations and activities in the vaccine ecosystem
View All Projects

Learn About Us

Our Story

We support public and non-profit clients in improving the implementation and evaluation of vaccine programmes and products with the goal of fostering healthier populations, globally.

How We Do It

For each project, we assemble the optimal team. Drawing on our worldwide network of experts, we pull together the right blend of skills and knowledge to successfully complete each project.

Our Impact

We have worked with partners on over 80 projects in 12 countries across the globe, bringing a science-driven approach to help strengthen vaccine and immunization programmes, mitigate the impact of vaccine-preventable diseases, and help save lives.

Learn More

Team Members in

4 cities

Clients in

16 cities

Research Conducted in

27 countries

Our Clients

Disclaimer: The organisations shown here indicate supplier-client relationships. MMGH has no formal relationship with these organisations nor does this listing indicate any form of endorsement of MMGH’s work beyond the award of past or present contract(s).

                   

Follow us on LinkedIn

Latest Publications

2026 - Journal Article

A prioritised research agenda to inform the introduction and use...

Lassa fever is a viral haemorrhagic disease endemic in West Africa, and several vaccine candidates are currently in development. To help ensure that future vaccine decisions are timely, evidence-informed, and aligned with country needs, we convened...
Publication
Building the evidence base for future Lassa fever vaccine decisions
Melissa Ko
Thomas Cherian
Shamim Qazi
View Publication
2026 - Journal Article

Priority implementation research for measles-rubella microarray patches identified using the...

Measles-rubella microarray patches are an innovative vaccine delivery technology in development that could help improve immunisation coverage and equity in low- and middle-income countries. To support future introduction, we used the Child Health and Nutrition Research...
Publication
Preparing for the introduction of measles-rubella microarray patches
Melissa Ko
Thomas Cherian
Shamim Qazi
View Publication
2026 - Journal Article

Evaluating the broader impact of improved influenza vaccines: A full...

Seasonal influenza remains a significant global public health challenge, causing substantial morbidity and mortality each year and there remains a need for more effective and durable influenza vaccines. To direct and accelerate research efforts, a full...
Publication
Adam Soble
Stefano Malvolti
View Publication
2026 - Journal Article

Health Worker Influenza Vaccination Programs: A Key to Pandemic Preparedness...

The COVID-19 pandemic created an urgent need to rapidly vaccinate health workers and the broader population. This analysis examined whether low- and middle-income countries with established influenza vaccination programs for health workers were better positioned to...
Publication
Carsten Mantel
View Publication
2024 - Journal Article

WHO Global Market Study on respiratory syncytial virus immunization products...

MI4A produces antigen-specific market studies, analyzing global demand and supply dynamics for products targeting a specific antigen. The Global Market Study on RSV Immunization Products aims to identify early potential obstacles to equitable access to RSV...
Publication
WHO
View Publication
2024 - Journal Article

An Application of an Initial Full Value of Vaccine Assessment...

Measles and rubella micro-array patches (MR-MAPs) are a promising innovation to address limitations of the current needle and syringe (N&S) presentation due to their single-dose presentation, ease of use, and improved thermostability. To direct and accelerate...
Publication
MDPI
Melissa Ko
Adam Soble
Stefano Malvolti
View Publication
View All Publications

Contact the MMGH Team

To find out how we can assist with your upcoming projects, please fill in this form and someone from our team will contact you shortly.

If you would like to join our team, please see our job openings here or send a speculative application by emailing your CV and a brief cover letter to info@mmglobalhealth.org

Headquarters:

MMGH Consulting GmbH
Kuerbergstrasse 1
8049 Zurich, Switzerland

+41 44 553 04 53

Branch:

MMGH Consulting GmbH
Chemin Maurice-Ravel 11C
1290 Versoix, Switzerland

+41 22 596 78 60